Hunter Syndrome clinical trials
9 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
- PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
- UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
- Registry of Patients Diagnosed With Lysosomal Storage Diseases
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
- Longitudinal Study of Neurodegenerative Disorders
- An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
- ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
- Early Check: Expanded Screening in Newborns
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Hunter Syndrome” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.